[1] |
Sawamura T,Kume N,Aoyama T,et al.An endothelial receptor for oxidized low-density lipoprotein[J].Nature,1997,386(6620):73-77.
|
[2] |
Aoyama T,Sawamura T,Furutani Y,et al.Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1(LOX-1)gene[J].Biochem J,1999,339(Pt 1):177-184.
|
[3] |
Sawamura T,Wakabayashi I,Okamura T.LOX-1 in atherosclerotic disease[J].Clin Chim Acta,2015,440C:157-163.
|
[4] |
Pirillo A,Norata GD,Catapano AL.LOX-1,OxLDL,and atherosclerosis[J].Mediators Inflamm,2013,2013(5):152-156.
|
[5] |
Chistiakov DA,Orekhov AN,Bobryshev YV.LOX-1-Mediated effects on vascular cells in atherosclerosis[J].Cell Physiol Biochem,2016,38(5):1851-1859.
|
[6] |
Sugano M,Tsuchida K,Makino N.Effects of soluble TNF-alpha receptor 1 on apoptosis induced by oxidized LDL in endothelial cells[J].Mol Cell Biochem,2004,258(1-2):57-63.
|
[7] |
Li L,Roumeliotis N,Sawamura T,et al.C-reactive protein enhances LOX-1 expression in human aortic endothelial cells:relevance of LOX-1 to C-reactive protein-induced endothelialdysfunction[J].Circ Res,2004,95(9):877-883.[8]Lubrano V,Balzan S.Roles of LOX-1 in microvascular dysfunction[J].Microvasc Res,2016,105:132-140.
|
[9] |
Nagase M,Hirose S,Sawamura T,et al.Enhanced expression ofendothelialoxidized low-density lipoprotein receptor(LOX-1)in hypertensive rats[J].Biochem Biophys Res Commun,1997,237(7):496-498.
|
[10] |
Chen M,Nagase M,Fujita T,et al.Diabetes enhances lectin-like oxidized LDL receptor-1(LOX-1)expression in the vascular endothelium:possible role of LOX-1 ligand and AGE[J].Biochem Biophys Res Commun,2001,287(7):962-968.
|
[11] |
Twigg MW,Freestone K,Homer-Vanniasinkam S,et al.The LOX-1 scavenger receptor and its implications in the treatment of vascular disease[J].Cardiol Res Pract,2012,2012(4):1-6.
|
[12] |
Pirillo A,Norata GD,Catapano AL.LOX-1,OxLDL,and atherosclerosis[J].Mediators Inflamm,2013,2013(5):782-786.
|
[13] |
Stancel N,Chen CC,Ke LY,et al.Interplay between CRP, atherogenic LDL,and LOX-1 and its potential role in the pathogenesis of atherosclerosis[J].Clin Chem,2016,62(2):320-327.
|
[14] |
Xu S,Ogura S,Chen J,et al.LOX-1 in atherosclerosis:biological functions and pharmacologicalmodifiers[J].Cell Mol Life Sci,2013,70(16):2859-2872.
|
[17] |
Gilmore TD,Herscovitch M.Inhibitors of NF-κB signaling:785 and counting[J].Oncogene,2006,25(51):6887-6899.
|
[15] |
Yoshimoto R,Fujita Y,Kakino A,et al.The discovery of LOX-1,its ligands and clinical significance[J].Cardiovasc Drugs Ther,2011,25(5):379-391.
|
[16] |
Steffel J.Tissue factor in cardiovascular diseases:molecularmechanisms and clin ical implications[J].Circulation,2006,113(5):722-731.
|
[18] |
Ayer JG,Song C,Steinbeck K,et al.Increased tissue factor activity inmonocytes from obese young adults[J].Clin Exp Pharmacol Physiol,2010,37(11):1049-1054.
|